Company Overview

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

  • Name

    Stryker Corporation

  • CEO

    Mr. Kevin A. Lobo

  • Website

    www.stryker.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1941

Profile

  • Market Cap

    $137.71B

  • EV

    $148.49B

  • Shares Out

    381.08M

  • Revenue

    $21.39B

  • Employees

    52,000

Margins

  • Gross

    64%

  • EBITDA

    25.53%

  • Operating

    20.71%

  • Pre-Tax

    18.78%

  • Net

    16.12%

  • FCF

    13.1%

Returns (5Yr Avg)

  • ROA

    7.05%

  • ROTA

    23.8%

  • ROE

    16.07%

  • ROCE

    12.51%

  • ROIC

    11.71%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $372.59

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $1,957M

  • Net Debt

    $10.79B

  • Debt/Equity

    0.64

  • EBIT/Interest

    12.44

Growth (CAGR)

  • Rev 3Yr

    9.6%

  • Rev 5Yr

    8.53%

  • Rev 10Yr

    8.7%

  • Dil EPS 3Yr

    18.01%

  • Dil EPS 5Yr

    -0.82%

  • Dil EPS 10Yr

    17.49%

  • Rev Fwd 2Yr

    8.57%

  • EBITDA Fwd 2Yr

    12.56%

  • EPS Fwd 2Yr

    12.56%

  • EPS LT Growth Est

    9.45%

Dividends

  • Yield

  • Payout

    34.74%

  • DPS

    $3.15

  • DPS Growth 3Yr

    8.52%

  • DPS Growth 5Yr

    9.19%

  • DPS Growth 10Yr

    10.32%

  • DPS Growth Fwd 2Yr

    8.2%

NYSE:SYK